Viral anti-inflammatory serpin reduces immuno-coagulopathic pathology in SARS-CoV-2 infection

ABSTRACT: Abstract: SARS-CoV-2 acute respiratory distress syndrome (ARDS) induces uncontrolled lung inflammation and coagulopathy with high mortality. Anti-viral drugs and monoclonal antibodies reduce early COVID-19 severity, but treatments for late-stage immuno-thrombotic syndromes and long COVID are limited. Serine protease inhibitors (SERPINS) regulate activated proteases. The myxoma virus-derived Serp-1 protein is a secreted immunomodulatory serpin that targets activated thrombotic, thrombolytic and complement proteases as a self-defense strategy to combat clearance. Serp-1 is effective in multiple animal models of inflammatory lung disease and vasculitis. Here, we describe systemic treatment with purified PEGylated Serp-1 as a therapy for immune-coagulopathic complications during ARDS. Treatmen

SUBMITTER: Prof. Alexandra, R Lucas 

PROVIDER: S-SCDT-10_15252-EMMM_202317376 | biostudies-other |

REPOSITORIES: biostudies-other